Rising costs may not be a result of orphan drugs

Published Online: Sep 12,2016 Laurie Toich, Assistant Editor From Daraprim’s price rising 5556% by Turing Pharmaceuticals under the leadership of Martin Shkreli, to the most recent pricing scandal with Mylan’s EpiPen, Americans have been faced with high out-of-pocket costs for many prescription drugs. Government institutions, such as the US Centers for Medicare and Medicaid, have begun crafting novel ways to reduce …

How long will markets sustain high priced orphan drugs?

The orphan drug market was worth more than $50 billion in 2011 and turns out blockbusters at the same rate as the broader industry, according to a recent Thomson Reuters analysis. This is mostly due to the high-prices of therapies developed by the industry for rare disease patients. Even though the segment has just started to provide a great source …